FIELD: medicine.
SUBSTANCE: group of inventions relates to diagnostics of stagnation of intra- and extracellular fluid in conditions of heart failure. Method for diagnosing stagnation of intra- and extracellular fluid in an individual with heart failure involves determining the level of proadrenomedullin or fragments thereof from at least 5 amino acids in a sample selected from whole blood, serum or plasma; correlation of said level of proadrenomedullin or its fragments with a degree of stagnation or diagnosis of stagnation, wherein an increased level above a threshold value is an indicator of stagnation or degree of stagnation, where said proadrenomedullin or a fragment thereof is selected from a group comprising MR-pro-ADM with SEQ ID NO: 3, mature ADM-NH2 with SEQ ID NO: 4, where threshold value is for mature ADM-NH2 with SEQ ID NO: 4 from 50 to 100 pg/ml, for MR-pro-ADM with SEQ ID No: 3 from 0.5 to 1.5 nmol/l. Also disclosed is a method for assessing stagnation or residual stagnation after a therapy or intervention in stagnation in an individual, using proadrenomedulline or fragments thereof for diagnosing stagnation or assessing or monitoring the degree of stagnation, to assess the elimination of stagnation or residual stagnation after therapy or intervention in case of stagnation.
EFFECT: group of inventions provides an early surrogate stagnation marker.
16 cl, 5 dwg, 22 tbl, 12 ex
Authors
Dates
2025-02-25—Published
2022-08-30—Filed